BioXcel Therapeutics Inc
Change company Symbol lookup
Select an option...
BTAI BioXcel Therapeutics Inc
AES AES Corp
CX Cemex SAB de CV
TPRE Third Point Reinsurance Ltd
BAC Bank of America Corp
KVHI KVH Industries Inc
SUP Superior Industries International Inc
FB Facebook Inc
V Visa Inc
FL Foot Locker Inc
Go

Health Care : Biotechnology |
Company profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Closing Price
$32.57
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
1,509,162
0

Company Profile

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
17.07x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

February 2020
Current Month
421.8K
Previous Month
442.5K
Percent of Float
5.04%
Days to Cover
0.9928 Days

Share Information

BTAI is in a share class of common stock
Float
10.6M
Shares Outstanding
20.4M
Institutions Holding Shares
59
26.00%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Peter MuellerChmn.
  • Vimal MehtaDir.
  • Richard I. SteinhartCFO
  • Frank D. YoccaCSO
  • Vincent J. O'NeillOther

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by , Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.